| 1 |
Strong HER-2 overexpression, Ki-67 high, strong Topoisomerase-II-α overexpression |
Pertuzumab, Trastuzumab and chemotherapy |
| 2 |
Strong EGFR overexpression, RAS wild-type, increased phosphorylation of Akt, activating PIK3CA mutation, activating KIT mutation |
Gemcitabine and Cisplatin plus Cetuximab |
| 3 |
Strong EGFR overexpression, KRAS mutation, increased phosphorylation of ERK1/2, MEK1/2 and Akt, moderately strong HER-2 overexpression (2+), no HER-2 amplification |
Everolimus |
| 4 |
Increased phosphorylation of ERK1/2, MEK1/2 and Akt, Ki-67 high, strong Topoisomerase-II-α overexpression |
Topotecan |
| 5 |
Strong EGFR overexpression, RAS wild-type, increased phosphorylation of MEK1/2 and Akt, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Panitumumab |
| 6 |
Moderately strong c-MET overexpression, weak expression of EGFR, increased phosphorylation of MEK1/2, Ki-67 high, low Topoisomerase-II-α expression |
Folinic acid, Fluorouracil and Irinotecan (FOLFIRI) |
| 7 |
Moderately strong EGFR overexpression, RAS wild-type, increased phosphorylation of ERK1/2, MEK1/2 and Akt, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Everolimus |
| 8 |
Strong EGFR overexpression, KRAS mutation, Ki-67 high, strong Topoisomerase-II-α overexpression |
Regorafenib |
| 9 |
Strong EGFR overexpression, RAS wild-type, strong HER-2 overexpression, activating PIK3CA mutation, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Trastuzumab and Lapatinib |
| 10 |
Moderately strong EGFR overexpression, KRAS mutation, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Folinic acid, Fluorouracil and Oxaliplatin (FOLFOX) and Bevacizumab, Regorafenib |
| 11 |
Weak EGFR overexpression, RAS wild-type, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Irinotecan and Panitumumab |
| 12 |
Moderately strong EGFR overexpression, KRAS mutation, weak VEGFR-2 expression, increased phosphorylation of ERK1/2 and MEK1/2, strong c-MET overexpression, no MET amplification, Ki-67 high, moderately strong Topoisomerase-II-α overexpression |
Fluorouracil and Irinotecan and Bevacizumab |
| 13 |
FLT3 mutation, Ki-67 high, low Topoisomerase-II-α expression |
Sunitinib |
| 14 |
Moderately strong EGFR overexpression, RAS wild-type |
Folinic acid, Fluorouracil and Irinotecan (FOLFIRI) and Cetuximab |
| 15 |
Strong EGFR overexpression, RAS wild-type |
Cisplatin and Gemcitabine |
| 16 |
Strong EGFR overexpression, RAS wild-type, increased phosphorylation of ERK1/2 and Akt, moderately strong HER-2 overexpression (2+), no amplification, Ki-67 high |
PIPAC (Pressurized Intra Peritoneal Aerosol Chemotherapy) |
| 17 |
Strong EGFR overexpression, RAS wild-type, increased phosphorylation of ERK1/2, Ki-67 high, strong Topoisomerase-II-α overexpression |
Vinorelbine and Cisplatin/Gemcitabine |
| 18 |
Moderately strong EGFR overexpression, RAS wild-type, Increased phosphorylation of ERK1/2, MEK1/2 and Akt, moderately strong c-MET overexpression, Ki-67 high, low Topoisomerase-II-α expression |
Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) |
| 19 |
Moderately strong EGFR overexpression, RAS wild-type, Ki-67 high, strong Topoisomerase-II-α overexpression |
Regorafenib |
| 20 |
Strong EGFR overexpression, RAS mutation status unknown, strong c-MET overexpression, no MET amplification, Ki-67 high, strong Topoisomerase-II-α overexpression |
Folinic acid, Fluorouracil and Irinotecan (FOLFIRI) |
| 21 |
Strong EGFR overexpression, KRAS mutation, moderately strong c-MET overexpression, no MET amplification, Ki-67 high, strong Topoisomerase-II-α overexpression |
Folinic acid, Fluorouracil and Oxaliplatin (FOLFOX) and Bevacizumab |
| 22 |
Strong EGFR overexpression, RAS wild-type, Ki-67 moderately high, low Topoisomerase-II-α expression |
Palliative radiation |
| 23 |
Strong EGFR overexpression, RAS wild-type, strong c-MET overexpression, no MET amplification |
Nivolumab |
| 24 |
Strong EGFR overexpression, RAS wild-type, activating EGFR mutation, Ki-67 high, strong Topoisomerase-II-α overexpression |
Radiotherapy, six months later Erlotinib |
| 25 |
Weak EGFR overexpression, RAS wild-type, moderately increased phosphorylation of MEK1/2 |
Adriamycin |
| 26 |
Moderately strong EGFR overexpression, RAS wild-type, moderately strong c-MET overexpression, no MET amplification, increased phosphorylation of ERK1/2 and MEK1/2 |
Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) |
| 27 |
Moderately strong EGFR overexpression, KRAS mutation, strong c-MET overexpression, no MET amplification, moderately strong EML4-ALK overexpression, ALK FISH negative, increased phosphorylation of MEK1/2, Ki-67 moderately high, low Topoisomerase-II-α expression |
Gemcitabine and nab-Paclitaxel |
| 28 |
Moderately strong EGFR overexpression, RAS mutation status unknown, moderately strong c-MET overexpression, no MET amplification, moderately strong EML4-ALK overexpression, ALK FISH negative, Ki-67 high, strong Topoisomerase-II-α overexpression |
Folinic acid, Fluorouracil and Irinotecan (FOLFIRI) and Bevacizumab |
